Table II.
Subgroup analysis and heterogeneity analysis of miR-23a/24-2/27a.
| Test of association | Test of heterogeneity | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Stratified analysis | No. of studies | Pooled HR (95% CI) | Z | P-value | Model | X2 | P-value | I2 (%) | ||
| miR-23a | ||||||||||
| OS | Overall | 7 | 2.33 (1.18–4.58) | 2.45 | 0.014 | R | 43.15 | 0.000 | 86.1 | |
| Cancer types | ||||||||||
| Digestive system | 2 | 2.46 (0.98–6.21) | 2.12 | 0.034 | R | 1.04 | 0.307 | 4.0 | ||
| Respiratory system | 3 | 2.03 (0.38–10.80) | 0.83 | 0.408 | R | 39.85 | 0.000 | 95 | ||
| Statistical methodology | ||||||||||
| Univariate analysis | 2 | 1.58 (0.08–30.81) | 0.30 | 0.76 | R | 23.23 | 0.000 | 95.7 | ||
| Multivariate analysis | 7 | 2.33 (1.18–4.58) | 2.45 | 0.014 | R | 43.15 | 0.000 | 86.1 | ||
| Ethnicity | ||||||||||
| Asian | 7 | 2.33 (1.18–4.58) | 2.45 | 0.014 | R | 43.15 | 0.000 | 86.1 | ||
| DFS/RFS | Overall | 3 | 1.13 (0.37–3.44) | 0.21 | 0.836 | R | 13.18 | 0.000 | 84.8 | |
| miR-24 | ||||||||||
| OS | Overall | 5 | 2.49 (1.84–3.37) | 6.91 | 0.000 | F | 4.90 | 0.298 | 18.4 | |
| Sample | ||||||||||
| Tissue | 3 | 2.74 (2.02–3.73) | 6.43 | 0.000 | F | 3.94 | 0.139 | 49.3 | ||
| Blood | 2 | 2.05 (1.22–3.45) | 2.60 | 0.000 | F | 0.07 | 0.792 | 0.0 | ||
| Cancer types | ||||||||||
| Digestive system | 3 | 2.99 (2.17–4.13) | 6.68 | 0.000 | F | 1.86 | 0.394 | 0.0 | ||
| Ethnicity | ||||||||||
| Asian | 3 | 2.99 (2.17–4.13) | 6.68 | 0.000 | F | 1.86 | 0.394 | 0.0 | ||
| Caucasian | 2 | 1.81 (1.13–2.88) | 2.48 | 0.013 | F | 0.00 | 0.977 | 0.0 | ||
| DFS/RFS | Overall | 4 | 2.85 (1.96–4.14) | 5.47 | 0.000 | F | 5.22 | 0.157 | 42.5 | |
| Sample | ||||||||||
| Tissue | 2 | 4.10 (2.40–7.00) | 5.18 | 0.000 | F | 1.66 | 0.198 | 39.7 | ||
| Blood | 2 | 2.00 (1.18–3.38) | 2.58 | 0.01 | F | 0.03 | 0.863 | 0.0 | ||
| MiR-27a | ||||||||||
| OS | Overall | 5 | 1.89 (1.32–2.69) | 3.48 | 0.001 | F | 6.38 | 0.173 | 37.3 | |
| Sample | ||||||||||
| Tissue | 3 | 1.50 (0.79–2.69) | 1.24 | 0.214 | R | 5.60 | 0.061 | 64.3 | ||
| Blood | 2 | 2.09 (1.36–3.22) | 3.36 | 0.001 | F | 0.07 | 0.792 | 0.0 | ||
| Cancer types | ||||||||||
| Osteosarcoma | 2 | 2.37 (1.52–3.68) | 3.82 | 0.000 | F | 0.42 | 0.515 | 0.0 | ||
| Ethnicity | ||||||||||
| Asian | 3 | 2.01 (1.32–3.05) | 3.25 | 0.001 | F | 0.79 | 0.675 | 0.0 | ||
| Caucasian | 2 | 1.60 (0.81–3.17) | 1.36 | 0.175 | R | 5.29 | 0.021 | 81.1 | ||
| DFS/RFS/PFS | Overall | 5 | 2.19 (1.29–3.70) | 2.92 | 0.003 | F | 2.21 | 0.698 | 0.0 | |
| Sample | ||||||||||
| Tissue | 3 | 2.58 (1.41–4.72) | 3.07 | 0.002 | F | 0.95 | 0.623 | 0.0 | ||
| Blood | 2 | 1.32 (0.46–3.80) | 0.51 | 0.608 | F | 0.10 | 0.753 | 0.0 | ||
| Cancer types | ||||||||||
| RCC | 2 | 2.30 (1.16–4.57) | 2.39 | 0.017 | F | 0.48 | 0.49 | 0.0 | ||
| Ethnicity | ||||||||||
| Asian | 4 | 1.95 (1.10–3.47) | 2.28 | 0.022 | F | 1.33 | 0.698 | 0.0 | ||
OS, overall survival; RFS, recurrence-free survival; PFS, progressionfree survival; CSS, cancer-specific survival; F, fixedeffects model; R, randomeffects model; RCC, renal cell carcinoma; HR, hazard ratio; CI, confidence interval.